One of the defining features of cells is their membranes. Each cell’s repository of DNA and protein-making machinery must be kept stable and secure from invaders and toxins. Scientists have attempted to replicate these properties, but, despite decades of research, even the most basic membrane structures, known as vesicles, still face many problems when made in the lab. They are difficult to make at consistent sizes and lack the stability of their biological counterparts.
Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting™, today announced that Mark E. Davis, Ph.D., Professor of Chemical Engineering at the California Institute of Technology, presented information about Cerulean's lead candidate, CRLX101, in a presentation entitled "Nanoparticle Delivery Platform for Solid Tumors" at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago on Monday, June 2nd.
Scientists at UC Santa Barbara have designed a nanoparticle that has a couple of unique — and important — properties. Spherical in shape and silver in composition, it is encased in a shell coated with a peptide that enables it to target tumor cells. What's more, the shell is etchable so those nanoparticles that don't hit their target can be broken down and eliminated. The research findings appear today in the journal Nature Materials.
Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.
Short, customized carbon nanotubes have the potential to deliver drugs to pancreatic cancer cells and destroy them from within, according to researchers at Rice University and the University of Texas MD Anderson Cancer Center.
NanoViricides, Inc. (the “Company”) reports that its CEO, Dr. Eugene Seymour, MD, MPH, will be presenting at the LD Micro Invitational Conference today at 5pm Pacific Time at the Luxe Sunset Boulevard Hotel in West Los Angeles.
Scientists from Nanyang Technological University (NTU) and the Singapore Eye Research Institute (SERI) have jointly developed a new nanomedicine that will allow glaucoma patients to do away with daily eye drops.
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Global Nanobiotechnology Applications, Markets and Companies Report 2014-2023" to their offering.
NANOBIOTIX, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced the successful completion of the first in human study of its lead NanoXray product, NBTXR3, which will be presented today at the American Society of Clinical Oncology (ASCO) annual meeting.
The first preclinical study of a new Rice University-developed anti-cancer technology found that a novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells — often by blowing them apart — without harming surrounding normal organs. The research, which is available online this week Nature Medicine, reports that Rice’s “quadrapeutics” technology was 17 times more efficient than conventional chemoradiation therapy against aggressive, drug-resistant head and neck tumors.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.